Back in December 2018, Merck reassigned development rights for a chimeric antigen receptor (CAR) T-cell product to Precigen. Doing so meant Precigen could regain full autonomous development of the CAR T therapies in exchange for $150 million in stock and a $25 million convertible note.

The convertible note would have been converted in December of this year but is instead being exercised ahead of its designated maturity.

Seattle Genetics, Merck partner on 2 oncology drug programs
Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate. Separately,...

Biopharma CEOs pledge commitment to safe vaccines
The CEOs from nine biopharmaceutical companies have pledged to remain committed to upholding the integrity of the scientific process as they work toward...

Precigen begins clinical trial for HPV-positive tumors
Precigen has dosed the first patients with Prgn-2009, an off-the-shelf investigational immunotherapy candidate, in a phase I/II clinical trial for the...

Microbe-based platform aims for sweet spot between biologics and gene therapy
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune...

Precigen touts heart failure multigenic therapy results
Precigen is highlighting clinical results from a phase I trial conducted by its subsidiary Precigen Triple-Gene that show that its multigenic investigational...